Literature DB >> 23016721

The role of microRNAs in the initiation and progression of stable atheromatous plaque.

Nikolaos Papageorgiou1, Dimitris Tousoulis, Emmanuel Androulakis, Anna Kontogeorgou, Marietta Charakida, Anastasios Giolis, Katerina Siama, Athanasios Trikas, Alexandros Briasoulis, Christos Pitsavos, Christodoulos Stefanadis.   

Abstract

Atherosclerosis is a chronic process related to several underlying mechanisms leading to the formation and evolution of atherosclerotic plaque. Of great interest are during the last years short, non-coding RNAs, called microRNAs and responsible for several aspects of homeostasis and disease. According to the available data microRNAs are expressed in the cardiovascular system and have key roles in normal states, as well as in disease development and progression. Moreover, it has been shown that they contribute to atherogenesis, coronary artery disease and myocardial infarction. Importantly, microRNAs circulate in the bloodstream, while they exist in tissues, affect plaque initiation and progression and seem to be essential biomarkers of atherosclerosis. Therefore, understanding the role of these molecules may be of great importance in the understanding of the pathogenesis of atheromatous plaque providing new evidence for diagnosis and treatment of atherosclerosis and its' clinical presentation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23016721

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Association between microRNAs and coronary collateral circulation: is there a new role for the small non-coding RNAs?

Authors:  Nikolaos Papageorgiou; Effimia Zacharia; Dimitris Tousoulis
Journal:  Ann Transl Med       Date:  2016-06

2.  CHOP Increases TRIB3-Dependent miR-208 Expression to Potentiate Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating TIMP3 in Atherosclerosis.

Authors:  Rui Chen; Yan Zhang; Chunyan Zhao
Journal:  Cardiovasc Drugs Ther       Date:  2021-04-15       Impact factor: 3.947

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.